期刊
NATURE CLINICAL PRACTICE NEUROLOGY
卷 2, 期 6, 页码 330-338出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ncpneuro0199
关键词
chromatin; histone deacetylase inhibitors; histories; Huntington's disease; transcription
资金
- NINDS NIH HHS [NS045242, NS038106] Funding Source: Medline
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS045242, R01NS038106] Funding Source: NIH RePORTER
Huntington's disease (HD) is an autosomal neurodegenerative disorder caused by a polyglutamine repeat expansion within the huntingtin protein. HD is characterized by problems with movement, cognition and behavioral functioning, and there is currently no effective treatment. Although multiple patholgic mechanisms have been proposed, the exact mechanism by which mutant huntingtin causes neural dysfunction is not known. Recent studies demonstrating altered messenger RNA expression point to transcriptional dysregulation as a central mechanism. The control os eukaryotic gene expression depends on modification of histone proteins associated with specific genes, with histone acetylation playing a crucial role. Studies in numerous HD models have shown that mutant huntingtin alters acetyltransferase activity, and indicate aberrant activity of this enzyme might be an underlying mechanism of transcriptional dysregulation is HD. Furthermore, recent studies have shown a therapeutic role for histone deacetylase inhibitors in a number of HD models. In this review, we summarize the current state of knowledge regarding the status of histones in HD. In addition, we discuss how these histone modifications not only lead to pathogenesis, but might also provide a novel therapeutic strategy for treating this devastating disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据